Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free CHGCY Stock Alerts

Chugai Pharmaceutical (CHGCY) Stock Forecast & Price Target

Chugai Pharmaceutical logo
$23.37 0.00 (0.00%)
As of 07/2/2026 04:00 PM Eastern
Compare

Chugai Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Buy
Based on 4 Analyst Ratings
Sell
0
Hold
1
Buy
3

Based on 4 Wall Street analysts who have issued ratings for Chugai Pharmaceutical in the last 12 months, the stock has a consensus rating of "Buy." Out of the 4 analysts, 1 has given a hold rating, 1 has given a buy rating, and 2 have given a strong buy rating for CHGCY.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for CHGCY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Chugai Pharmaceutical and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CHGCY Analyst Ratings Over Time

TypeCurrent Forecast
7/5/25 to 7/5/26		1 Month Ago
6/5/25 to 6/5/26		3 Months Ago
4/6/25 to 4/6/26		1 Year Ago
7/5/24 to 7/5/25
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
 N/A
Buy
1 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
 N/A
Hold
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
 N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
 N/A
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingBuyBuyStrong BuyN/A

CHGCY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CHGCY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Chugai Pharmaceutical Stock vs. The Competition

TypeChugai PharmaceuticalMedical CompaniesBroader Market
Consensus Rating Score
3.25
2.30
2.52
Consensus RatingBuyHoldModerate Buy
Predicted UpsideN/A715.96% Upside13.30% Upside
News Sentiment Rating
Neutral News

See Recent CHGCY News
Positive News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
6/15/2026
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
3 of 5 stars
 UpgradeHold ➝ Buy
5/29/2026
Zacks Research logo
Zacks Research
Not Rated
 UpgradeHold
2/25/2026
Smbc Nikko Sec. logo
Smbc Nikko Sec.
Not Rated
 UpgradeStrong-Buy
1/27/2026
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeStrong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:28 PM ET.


Should I Buy Chugai Pharmaceutical Stock? CHGCY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, July 1, 2026. Please send any questions or comments about these Chugai Pharmaceutical pros and cons to contact@marketbeat.com.

Chugai Pharmaceutical
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Chugai Pharmaceutical Co., Ltd.:

  • The current stock price is around $23.43, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Chugai Pharmaceutical Co., Ltd. has a strong portfolio of oncology products, including the latest versions of Avastin and Tecentriq, which are widely used in cancer treatment and have significant market demand.
  • The company is involved in various strategic alliances, particularly with Roche Group, which can enhance its research capabilities and market reach, potentially leading to increased revenue.
  • Chugai Pharmaceutical Co., Ltd. is actively developing new product candidates across multiple therapeutic areas, including immunology and neuroscience, which could diversify its revenue streams and reduce risk.
  • With a recent average daily trading volume of approximately 381,100 shares, the stock shows good liquidity, making it easier for investors to enter and exit positions.

Chugai Pharmaceutical
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Chugai Pharmaceutical Co., Ltd. for these reasons:

  • The company has a relatively low short percentage of float, indicating that there may be limited investor confidence in the stock's short-term performance.
  • Chugai Pharmaceutical Co., Ltd. has reported a month-to-month change in shares shorted, suggesting some volatility in investor sentiment.
  • Institutional ownership is currently at 0%, which may indicate a lack of confidence from larger investors, potentially affecting stock stability.
  • With no outstanding shares reported, there may be concerns about the company's market presence and ability to attract new investments.
  • The company has experienced a significant decrease in shares shorted over the previous month, which could signal a bearish outlook among some investors.

CHGCY Forecast - Frequently Asked Questions

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chugai Pharmaceutical in the last twelve months. There is currently 1 hold rating, 1 buy rating and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CHGCY shares.

According to analysts, Chugai Pharmaceutical's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Chugai Pharmaceutical's stock had 2 upgrades by analysts.

Chugai Pharmaceutical has been rated by research analysts at The Goldman Sachs Group, and Zacks Research in the past 90 days.

Analysts like Chugai Pharmaceutical more than other "medical" companies. The consensus rating for Chugai Pharmaceutical is Buy while the average consensus rating for "medical" companies is Hold. Learn more on how CHGCY compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Chugai Pharmaceutical Recommendations


This page (OTCMKTS:CHGCY) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel